Old Web
English
Sign In
Acemap
>
authorDetail
>
Michael C. Cameron
Michael C. Cameron
Pfizer
moderate to severe
in patient
Medicine
Atopic dermatitis
Placebo
2
Papers
1
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
2021
Journal of The American Academy of Dermatology
Andrew Blauvelt
Jonathan I. Silverberg
Charles Lynde
Thomas Bieber
Samantha Eisman
Jacek Zdybski
Walter Gubelin
Eric L. Simpson
Fernando Valenzuela
Paulo Ricardo Criado
Mark Lebwohl
Claire Feeney
Tahira Khan
Pinaki Biswas
Marco DiBonaventura
Hernan Valdez
Michael C. Cameron
Ricardo Rojo
Show All
Source
Cite
Save
Citations (0)
Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
2021
Melinda Gooderham
Chia-Yu Chu
Ricardo Rojo
Hernan Valdez
Pinaki Biswas
Michael C. Cameron
Claire Feeney
Gerardo A. Encinas
Kathleen Peeples-Lamirande
Joseph C. Cappelleri
Daniela E. Myers
Marco DiBonaventura
Show All
Source
Cite
Save
Citations (1)
1